Literature DB >> 7844385

Systemic immunoprophylaxis of nasal respiratory syncytial virus infection in cotton rats.

I R Sami1, F M Piazza, S A Johnson, M E Darnell, M G Ottolini, V G Hemming, G A Prince.   

Abstract

The cotton rat model was used to test whether systemically administered immunoglobulin could protect nasal tissues against low challenge doses of respiratory syncytial virus (RSV). Animals were pretreated by intraperitoneal injection of human immunoglobulin with moderate (1:2226) or high (1:15,000) neutralizing antibody titers to RSV (day 0), challenged intranasally with RSV Long at doses ranging from 10(1) to 10(5) pfu (day 1), and sacrificed for virus titration (day 5). Pretreatment with moderate-titer immunoglobulin effected complete or near complete nasal protection against low to moderate (10(1)-10(3) pfu) RSV challenge doses and a significant reduction in nasal RSV titers at high (10(4)-10(5) pfu) challenge doses. Pretreatment with high-titer immunoglobulin effected near complete nasal protection at an RSV challenge dose of 10(3) pfu and highly significant and significant reductions in nasal RSV titers at challenge doses of 10(4) and 10(5) pfu, respectively. Immunoprophylaxis effected complete or near complete pulmonary protection at all RSV challenge doses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7844385     DOI: 10.1093/infdis/171.2.440

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

Review 1.  Genetic and structural determinants of virus neutralizing antibodies.

Authors:  J E Crowe; R O Suara; S Brock; N Kallewaard; F House; J H Weitkamp
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Mathematical modelling identifies the role of adaptive immunity as a key controller of respiratory syncytial virus in cotton rats.

Authors:  Darren Wethington; Olivia Harder; Karthik Uppulury; William C L Stewart; Phylip Chen; Tiffany King; Susan D Reynolds; Alan S Perelson; Mark E Peeples; Stefan Niewiesk; Jayajit Das
Journal:  J R Soc Interface       Date:  2019-11-27       Impact factor: 4.118

Review 3.  Intranasal antibody prophylaxis for protection against viral disease.

Authors:  R Weltzin; T P Monath
Journal:  Clin Microbiol Rev       Date:  1999-07       Impact factor: 26.132

4.  Robust IgA and IgG-producing antibody forming cells in the diffuse-NALT and lungs of Sendai virus-vaccinated cotton rats associate with rapid protection against human parainfluenza virus-type 1.

Authors:  R Sealy; B G Jones; S L Surman; J L Hurwitz
Journal:  Vaccine       Date:  2010-08-01       Impact factor: 3.641

Review 5.  The use of a neonatal mouse model to study respiratory syncytial virus infections.

Authors:  Stephania A Cormier; Dahui You; Srinivasa Honnegowda
Journal:  Expert Rev Anti Infect Ther       Date:  2010-12       Impact factor: 5.091

6.  Detection of respiratory syncytial virus using nanoparticle amplified immuno-polymerase chain reaction.

Authors:  Jonas W Perez; Elizabeth A Vargis; Patricia K Russ; Frederick R Haselton; David W Wright
Journal:  Anal Biochem       Date:  2010-11-25       Impact factor: 3.365

7.  Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.

Authors:  Hoyin Mok; Sujin Lee; Thomas J Utley; Bryan E Shepherd; Vasiliy V Polosukhin; Martha L Collier; Nancy L Davis; Robert E Johnston; James E Crowe
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

8.  Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates.

Authors:  John T Bates; Jennifer A Pickens; Jennifer E Schuster; Monika Johnson; Sharon J Tollefson; John V Williams; Nancy L Davis; Robert E Johnston; Nancy Schultz-Darken; James C Slaughter; Frances Smith-House; James E Crowe
Journal:  Vaccine       Date:  2016-01-07       Impact factor: 3.641

9.  Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model.

Authors:  Bart G Jones; Robert E Sealy; Sherri L Surman; Allen Portner; Charles J Russell; Karen S Slobod; Philip R Dormitzer; John DeVincenzo; Julia L Hurwitz
Journal:  Vaccine       Date:  2014-04-14       Impact factor: 3.641

Review 10.  Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field.

Authors:  Prasad S Kulkarni; Julia L Hurwitz; Eric A F Simões; Pedro A Piedra
Journal:  Viral Immunol       Date:  2018-01-16       Impact factor: 2.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.